Asia Pacific Biotechnology Market (2008-2012)

Bharatbook.com is glad to announce a new report titled â??Asia Pacific Biotechnology Market (2008-2012)â?.

Asia Pacific Biotechnology Market provides an updated and detailed overview of the Asia-Pacific Biotechnology industry. It examines the emerging trends and provides exclusive forecasts and segment-wise snapshots of the Biotechnology industry in the region. The report also presents the information regarding the government policies on Biotechnology and region-wise Bioclusters in the Asia-Pacific countries.

Key Findings

Growing at an estimated CAGR of 11.23% between 2004 and 2006, the expected value of Asia-Pacific Biotechnology market by 2006 end is more than US$ 39.16 Billion.

Japan, China, and Taiwan are the largest Biotechnology markets in the Asia-Pacific region that had a combined market share of nearly 76% in 2006.

The Asia-pacific region will emerge as a key destination for clinical trials & stem cell research.

Biotechnology will play an important role in agriculture sector by developing large number of genetically modified (GM) crops.

Biopharma industry, comprising of vaccines, therapeutics, diagonostics and other products, will emerge as a major segment of the Asia-Pacific Biotech industry.

The Biotechnology industry in the Asia-pacific region is largely dependent on the government with very little private participation in most of the countries.

Lack of venture funding remains a major challenge for Asia-Pacific Biotechnology companies.

The Contract Research industry in India could reach as high as US$ 270 Million by 2009.

The Japanese Government, which was earlier accused of shielding its domestic companies, has now opened its doors for foreign investment.

Opaque government policies and regulations in China are acting as a major hurdle for foreign participation in the biotechnology market.

For further information kindly visit: http://www.bharatbook.com/detail.asp?id=50042

OR Contact us at
 
Bharat Book Bureau
207, Hermes Atrium, Sector 11, PO Box.54,
CBD Belapur, Navi Mumbai – 400 614, India.
Phone: +91 22 2757 8668 / 2757 9438
Fax: +91 22 2757 9131
E-mail: info@bharatbook.com
Website: www.bharatbook.com

 

Asia Pacific Biotechnology Market (2008-2012) by Marketsmonitor.com

The biotechnology market in Asia-Pacific region looks very lucrative from investment perspective as it has enjoyed double-digit growth in past few years. The industry is attracting more and more private investments in wake of immense growth opportunities and vast untapped biotech markets. Identifying the future growth potential of the industry, the governments of different countries in the Asia-Pacific region are taking up various initiatives to promote research in the region. Overall, the Asia-Pacific biotech market is expected to spur future growth in the global biotechnology market.

According to our new research report, “Asia Pacific Biotechnology Market (2008-2012)”, the Asia-Pacific biotech market is projected to grow at a CAGR of around 14% during 2010-2012. Currently, the industry is driven by new developing markets like Malaysia and India where developments in the sector are on a full swing. Anticipating the future growth, governments are promoting the industry by making investments and implementing new strategies.

Our research has found that Japan and China are dominating the industry. While higher growth rate has been witnessed in emerging markets like Malaysia, Japan and China are anticipated to dominate the market in future with combined share of around 70% of overall market. In this regard, our report provides rational analysis of various factors which will drive this market over the forecast period.

The report also provides extensive information and data of the biotech market in the Asia-Pacific region as well as discusses the emerging trends like contract research and manufacturing, bioinformatics, generics market etc. It provides valuable information to pharmaceutical & biotechnology companies and investors looking to enter these markets and help them to devise strategies in accordance to the individual markets. The report also contains detailed analysis and statistics of the market size, growth, share, segmentation, geographic distribution and trends in technology development.

For more detail visit :- http://www.marketsmonitor.com/Asia-Pacific-Biotechnology-Market-2008-2012-Report/IM138.htm

SEO Company Delhi

—————————————————————————————————————-

Issued By        :    Marketsmonitor.com
Contact Email        :    sales@marketsmonitor.com
Country            :    India
Categories        :    Biotech, Research, Technology
Tags            :    biotechnology market

Pharmaceutical Outsourcing: Opportunity for India!

The global pharmaceutical markets were estimated at US$712bn in the year 2008 growing at 6.4 percent over 2006. This has grown at a compounded annual growth rate (CAGR) of 10.7 percent for the period 2002-07. The market size of USA is estimated at US$295-305bn with an estimated growth rate of 4-5 percent. It is followed by Top 5 European countries (EU-5) with an estimated market size of US$135-145bn growing at 4-5%, emerging markets VIZ., Brazil, China, India, Mexico, Russia, South Korea and Turkey with an estimated market size of US$85-90bn. (growing at 12-13%) and Japan with an estimated market size of US$64-68bn (growing at 1-2%). The pharmaceutical market size of the rest of the world (ROW) is estimated at US$125-135bn which is estimated to grow at 7-8 percent in the coming years.

The Indian Pharmaceuticals sector has come a long way, being almost non-existing during 1970, to a prominent provider of health care products, meeting almost 95% of country’s pharmaceutical needs. The pharmaceutical sector is emerging as one of the major contributors to Indian exports with export earnings rising from a negligible amount in early 1990s to Rs.29,139.57 crores by 2007-08. The exports of Drugs,  pharmaceuticals & fine chemicals of India were growing at a compounded annual growth rate (CAGR) of 17.8% during the five year period 2003-04 to 2007-08.

The Indian domestic pharmaceutical market size is estimated at US$10.76 bn in the year 2008 and is expected to grow at a high CAGR of 9.9% percent till 2010 and thereafter at a CAGR of 9.5% till 2015. Currently, the Indian pharmaceutical industry is one of the world’s largest and most developed, ranking 4th in volume terms and 13th in value terms. The country accounted for 8 percent of global production and 2 percent of world markets in pharmaceuticals. Most of the domestic pharmaceutical drug requirements are met by the domestic industry. In the seg ment of Active Pharmaceutical Ingredients (APIs) India ranks third in the world producing about 500 different APIs.

Currently, India is recognised as a high-quality, low-cost skilled producer of pharmaceuticals. It is seen not only as a manufacturing base for APIs and formulations, but also as an emerging hub for biotechnology, bioinformatics, contract research, clinical data management and clinical trials.

India has achieved the distinction of providing healthcare at very low cost while maintaining profitability. India exports full basket of pharmaceutical products comprising intermediates, APIs, Finished Dosage Combinations (FDCs), biopharmaceuticals, vaccines, clinical services, etc., to various parts of the world.

At present, India is among the top 20 pharmaceutical exporters world-wide and with the largest number of US FDA inspected plants (119 plants), outside the USA. Various other agencies like MHRA UK, MCA South Africa, TGA Australia , HPB Canada have approved scores of plants in India.

India accounts for over one third of drug master files (DMFs) in USA. Thirty percent of all approved ANDAs in the US are from India, ranking the country number 2 next only to USA. Needless to mention scores of approvals by UK MHRA and various other agencies are also being filed from India. India ranks only next to USA with a share of 21 percent of patent challenges. This justifies that India is an emerging leader in pharmaceuticals.

The indigenous pharma market in value terms accounts for 1% of global pharmaceutical market and 8% in volume terms.  Market growth be ment of Active Pharmaceutical Ingredients (APIs) India ranks third in the world producing about 500 different APIs.

Currently, India is recognised as a high-quality, low-cost skilled producer of pharmaceuticals. It is seen not only as a manufacturing base for APIs and formulations, but also as an emerging hub for biotechnology, bioinformatics, contract research, clinical data management and clinical trials.

India has achieved the distinction of providing healthcare at very low cost while maintaining profitability. India exports full basket of pharmaceutical products comprising intermediates, APIs, Finished Dosage Combinations (FDCs), biopharmaceuticals, vaccines, clinical services, etc., to various parts of the world.

At present, India is among the top 20 pharmaceutical exporters world-wide and with the largest number of US FDA inspected plants (119 plants), outside the USA. Various other agencies like MHRA UK, MCA South Africa, TGA Australia , HPB Canada have approved scores of plants in India.

India accounts for over one third of drug master files (DMFs) in USA. Thirty percent of all approved ANDAs in the US are from India, ranking the country number 2 next only to USA. Needless to mention scores of approvals by UK MHRA and various other agencies are also being filed from India. India ranks only next to USA with a share of 21 percent of patent challenges. This justifies that India is an emerging leader in pharmaceuticals.

The indigenous pharma market in value terms accounts for 1% of global pharmaceutical market and 8% in volume terms.  Market growth be fore 2005 of domestic pharma industry was primarily driven by a number of new product launches by both Indian and foreign company.  The Indian market started to attract a number of foreign players with the implementation of product patent in January 2005. The FDI in pharma industry is estimated at US$ 172 million during 2005-06, recording a CAGR of 62.6% during the period beginning 2002-06.

India has the advantage of offering three distinct waves of opportunities in offshoring over the next decade. The first wave basically focuses on developing drugs “faster and cheaper” and extends from chemistry research to clinical trials to manufacturing. The sources of advantage are twofold: a cheaper skilled talent base — chemists, MDs, nurses, quality control personnel — along with the ability to expedite recruiting for trials due to a large naïve patient base.

The second wave, which is likely to become mainstream over the next 3 to 5 years, will extend the breadth of capabilities to include more complex manufacturing to produce injectables; targeted and cutting edge clinical trials, including adaptive and proof of concept trials; and more sophisticated biology- based research platforms.

Around 2013-2015, the third opportunity wave is expected to occur when Indian drug manufacturers are likely to start manufacturing biologics (recombinant proteins) and offer cutting-edge disruptive R&D platforms such as pharmacogenetics and cheminformatics.

Bioinformatics Tools Cutting Cost & Time for Drug Discovery

According to a new research report – “Global Bioinformatics Market Outlook”- by RNCOS, the worldwide bioinformatics industry has seen a double-digit growth rate in the past few years and is forecasted to record a stupendous CAGR of 16.3% from 2007 to 2010.

The report says that the pressure of developing new drugs is intensifying on the global drug industry as existing drugs will go off-patent soon and costs of R&D are escalating sharply, making the companies to switch to bioinformatics. Therefore, the global bioinformatics industry will be led by increasing outlay on obtaining the bioinformatics tools and services by pharmaceutical and biotechnology companies to accelerate their drug discovery process.

Currently, the report says, an average drug takes approximately 10 years to reach clinical phase from the discovery phase and costs between US$ 400 Million and over US$ 1 Billion to the company, with much of the spending incurred at the final stages of the development. However, this huge cost of the drug development process can be cut down substantially by using bioinformatics and Computer-Aided Drug Design. For instance, the application of bioinformatics in the discovery and development of some new drug may reduce the annual cost and time by 33% and 30% respectively.

Other than cost and time benefit, blending of IT and life sciences, on one side, is helping the pharma companies to successfully overcome the challenges faced in collecting, processing, storing and analyzing data during the drug development process, and on the other side, pushing up the bioinformatics market, says the RNCOS research.

However, as the industry is at a nascent stage in most parts of the world, the market growth is hard to predict but it will certainly grow at a double-digit rate by 2010.

The report gives an exhaustive account on the global bioinformatics industry and provides forecast on its various segments, including drug patent expirations, bioinformatics market by segment, analysis software & service market, analysis software & service market by application, IT infrastructure & other services market, and drug delivery market.

“Global Bioinformatics Market Outlook” gives updated and detailed information on the industry and examines the emerging market trends. It offers an insight into the market and examines the bioinformatics market in major countries.

For more information visit: http://rncos.com/Report/IM554.htm
Current Industry News: http://www.rncos.com/Blog/

Indian IVD Emerging as One of the Fastest Growing Segments

Advances in human genomics, bioinformatics, miniaturization, and microelectronics often blended with information and computer technology have led to a growth spurt in the global market for in vitro diagnostic (IVD) tests. Among others, Indian IVD market is anticipated to grow at a CAGR of around 15% during 2009-2012, emerging as Asia’s third largest IVD market after Japan and China, says our econometric study “Global In Vitro Diagnostic Market Analysis”. This growth rate compares with a CAGR of around 9% in the global IVD market during the same period.

We have done extensive research on the global IVD market in order to monitor various trends and developments undergoing across the key IVD markets. We have found that although Indian IVD market is very small compared to the global IVD market, it is growing at a rapid pace to outperform other major markets in near future. “Various factors, such as increasing urbanization, unhealthy diets and growing sedentary lifestyle, have strongly boosted the prevalence of lifestyle-related diseases such as diabetes and cardiovascular diseases in the country. Owing to these factors Indian IVD market is projected to grow at double the pace of the global IVD market,” says a research analyst at RNCOS.

We have observed that growing health consciousness among middle- and high-income families in India is heralding a new business opportunity. This has shifted focus from in-patient treatment to a regular preventive health check. For example, corporate companies offer annual health check for their employees, insurance companies conduct pre-insurance policy check, and self paid health checks also give out a potential business opportunity.

Our study analyzes the key markets and segments of Industry to give a brief about the future scenario of the industry. The technological factors driving the growth are improving techniques, lab automation process, improved data delivery system, etc. According to our industry experts, several steps should be taken by IVD manufacturers to invest in dedicated research and development.

“Global In Vitro Diagnostic Market Analysis” includes detailed analysis of the factors which are fueling the growth of Indian IVD market. Besides this, report also provides rational analysis and forecast on various segments and sectors of the industry.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM103.htm

Check DISCOUNTED REPORTS on: http://www.rncos.com
# # #

About RNCOS:

RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today’s globally competitive environment.